Published online Jun 25, 2015. doi: 10.4253/wjge.v7.i7.670
Peer-review started: March 16, 2015
First decision: April 10, 2015
Revised: April 24, 2015
Accepted: May 8, 2015
Article in press: May 11 2015
Published online: June 25, 2015
Processing time: 116 Days and 5.6 Hours
Patients with indeterminate colitis (IC) are significantly younger at diagnosis with onset of symptoms before the age of 18 years with significant morbidity in the interim. The successful care of IC is based on microscopic visual predict precision of eventual ulcerative colitis (UC) or Crohn’s colitis (CC) which is not offered in 15%-30% of inflammatory bowel disease (IBD) patients even after a combined state-of-the-art classification system of clinical, visual endoscopic, radiologic and histologic examination. These figures have not changed over the past 3 decades despite the introduction of newer diagnostic modalities. The patient outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis may be painstaking if IC turns into CC. Our approach is aiming at developing a single sensitive and absolute accurate diagnostic test tool during the first clinic visit through endoscopic biopsy derived proteomic patterns. Matrix-assisted-laser desorption/ionization mass spectrometry (MS) and/or imaging MS technologies permit a histology-directed cellular test of endoscopy biopsy which identifies phenotype specific proteins, as biomarker that would assist clinicians more accurately delineate IC as being either a UC or CC or a non-IBD condition. These novel studies are underway on larger cohorts and are highly innovative with significances in differentiating a UC from CC in patients with IC and could lend mechanistic insights into IBD pathogenesis.
Core tip: This Editorial is introductory, dedicated to a novel and innovative study with clinical relevance regarding precision of indeterminate colitis (IC) into accurate diagnosis of either ulcerative colitis (UC) or Crohn’s colitis (CC). To date, it is very difficult to predict the clinical course of IC, whether it will evolve into UC or CC. About 90% of IC is diagnosed at the time of colectomy for fulminant colitis and subsequent management critically depends on the correct eventual diagnosis. The outcome after colectomy and pouch anastomosis may be painstaking if IC turns into CC. The undergoing studies of proteomic analysis on colon biopsy specimens, if successful will permit delineate IC into UC or CC precision which could be of great help in decision making regarding treatment indication. Although the present data is convincing and support differentiated between UC and CC, this data requires validation and confirmation on a large scale by clinical studies. Hopefully, this editorial will stimulate research into this field to trying to overcome the diagnostic accuracy challenges in inflammatory bowel diseases.